Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

A Blast from the Past article by Pinnacle Digest the day before Breathtec IPO @ CSE

It's an entertaining read to say the least.

Excerpts:

We asked Michael T. Costanzo, Ph.D., CEO of Breathtec Biomedical, about some of the differences between Breathtec's technology and others mentioned:

"Menssana uses a technique called GC that separates compounds of interest from the rest. However, both Owlstone and Breathtec use a different technique called FAIMS that filters out undesired compounds leaving only those we want to monitor for disease screening, and both are capable of doing so in a fraction of the time. FAIMS can be performed in seconds, whereas GC takes minutes if not hours to run a single sample. The primary difference between Owlstone and Breathtec is the innerworkings of the device itself. Firstly, Breathtec's device allows direct device validation by mass spectrometry (the gold standard when it comes to identifying and validating analyses). Simpy put, our device would be capable of running either standalone or on an MS instrument depending on the type of analysis required. This is something the Lonestar would lack as it is a standalone device that is not capable of also attaching to this MS instrument. Secondly, while Owlstone currently produces a smaller device, experiments suggest it does not prove adequate to monitor endogenous compounds for disease detection. Endogenous compound are any compound that is produced inside the body, and are the primary markers for disease. Therefore, even though Owlstone's Lonestar system can analyze a moderate range of volatile compounds found in a high concentration in the body, it has trouble distinguishing lower volatility compounds and at lower concentrations; two areas our device should be proficient at."

- Michael T. Costanzo, Ph.D., CEO of Breathtec

Towards the conclusion of his CEO message, Costanzo states:

"I think it safe to say the value of early screening could be measured in billions of dollars annually around the globe. To that end, we have already secured a key patent in this potentially high growth sector..."

Some of our long-time readers may remember Mr. Malhi as he is a co-founder and President of Cannabix Technologies (CSE:BLO), a company we introduced in July of 2014. Cannabix is developing a prototype marijuana breathalyzer device. It has received press coverage from Huffington Post Canada, VICE News, Yahoo News, The Globe and Mail, Time Magazine, and many other networks. Its shares didn't perform too badly either; as more investors learned about the technology its stock provided early investors with a significant profit taking opportunity. We introduced it to our readers in July of 2014 when it had last traded at $0.26. By February, 2015, approximately 8-months later, it hit an all-time high of $0.77...

https://myemail.constantcontact.com/Starts-trading-tomorrow---.html?soid=1101420438425&aid=WFgJwepaPZo




/////AMG